ASCO 2022 | PRINCE: 177Lu-PSMA-617 and pembrolizumab in prostate cancer
Anis Hamid, MBBS, Dana-Farber Cancer Institute, Boston, MA, describes the trial design of the phase I PRINCE trial (NCT03658447), which assessed 177Lu-PSMA-617, a PSMA-targeted radioligand therapy, plus pembrolizumab for patients with metastatic castration resistant prostate cancer (mCRPC). A majority of these patients will have progressed on existing therapies such as docetaxel, and the trial will additionally ascertain the efficacy of circulating tumour cells (CTCs) and PSMA positron emission tomography (PET) scans as biomarkers of prognosis. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Transcript (edited for clarity)
So the PRINCE study, to those who aren’t familiar, is a Phase I trial, fully accrued and completed, and in follow up now of treatment for metastatic castration resistant, prostate cancer. It’s combining two therapies. One is Lutetium PSMA radioligand treatment with the checkpoint inhibitor, pembrolizumab. This population of patients are men with castration-resistant prostate cancer who have progressed after an androgen receptor signaling inhibitor, and they may have progressed after chemotherapy like docetaxel as well...
So the PRINCE study, to those who aren’t familiar, is a Phase I trial, fully accrued and completed, and in follow up now of treatment for metastatic castration resistant, prostate cancer. It’s combining two therapies. One is Lutetium PSMA radioligand treatment with the checkpoint inhibitor, pembrolizumab. This population of patients are men with castration-resistant prostate cancer who have progressed after an androgen receptor signaling inhibitor, and they may have progressed after chemotherapy like docetaxel as well. The PRINCE study, which is being presented at ASCO 2022 as well today does show significant activity for that combination in castration-resistant disease. The focus of our substudy was to look at correlatives of that trial, in particular profiling of circulating tumor cells and PET metrics as potential prognostic and predictive biomarkers for combined Lutetium plus pembrolizumab therapy.
Read more...
